Pune: Hikal, a BSE- and NSE-listed company, which is a partner to global pharmaceutical, crop protection, and specialty chemical companies, has announced the commissioning of its enhanced current Good Manufacturing Practice (cGMP)-compliant pilot plant facility at its Pune Research & Technology (R&T) campus.Hikal partners with companies across the pharmaceutical, animal health, crop protection, and specialty chemical industries, manufacturing and supplying active ingredients, intermediates, and biocides to the global life sciences sector.“The expansion strengthens Hikal's integrated capabilities across process development, scale-up, technology transfer, and clinical-stage manufacturing at its Pune Innovation Campus. This enables the company to partner more effectively with global pharmaceutical customers from early development through to commercial manufacturing readiness,” Hikal said in a media release.Also read | Trump's Generic Drug Tariffs Explained: What it means for Indian pharma“By creating a stronger bridge between laboratory-scale research and commercial-scale production, the facility is designed to help customers accelerate development timelines, improve process robustness, and generate high-quality material for regulated development programmes,” the release added.The company noted that the pilot plant allows for the manufacture and supply of preclinical and clinical-phase development materials directly from the R&T campus. This setup enables scientists and engineers to closely monitor processes, enhance cross-functional collaboration, and reduce technology-transfer timelines to ensure timely project delivery.Also read | Inside IndiGo's succession plan: Rahul Bhatia prepares son Madhav for future leadershipSameer Hiremath, Vice Chairman and Managing Director of Hikal, said: “The commissioning of our cGMP pilot plant is an important step in strengthening Hikal’s pharmaceutical development and scale-up platform. It enhances our ability to support customers as they transition from laboratory development to larger-scale clinical programmes, while staying firmly anchored in quality, safety, and compliance.”